Tango Therapeutics Doses First Patient in Phase 1/2 Trial for TNG456 in MTAP-Deleted Glioblastoma and Solid Tumors

Tango Therapeutics has announced the dosing of the first patient in its Phase 1/2 trial for TNG456, a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor, targeting patients with MTAP-deleted solid tumors, particularly glioblastoma (GBM). Preclinical studies show strong potency and MTAP-selectivity for TNG456, with 45% of GBM cases being MTAP-deleted and promising brain exposure levels. The trial aims to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity of TNG456 as a monotherapy and in combination with abemaciclib.